Corticosterone accelerates atherosclerosis in the apolipoprotein E-deficient mouse

Atherosclerosis

Volumn 232, Issue 2, 2014, Pages 414-419

  Okutsu, Mitsuharu ^a   Lira, Vitor A ^b,d   Higashida, Kazuhiko ^a   Peake, Jonathan ^c   Higuchi, Mitsuru ^a   Suzuki, Katsuhiko ^a  

^a WASEDA UNIVERSITY   (Japan)

^b UNIVERSITY OF IOWA   (United States)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

ApoE deficient mice; Cholesterol; Dyslipidaemia; Hypothalamic pituitary adrenal axis; Stress

Indexed keywords

CHOLESTEROL; CORTICOSTERONE; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN; SMALL DENSE LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; AORTA ROOT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CHRONIC STRESS; CONTROLLED STUDY; DISEASE ASSOCIATION; LEUKOCYTE; LIPOPROTEIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

APOE-DEFICIENT MICE; CHOLESTEROL; DYSLIPIDAEMIA; HYPOTHALAMIC-PITUITARY-ADRENAL AXIS; STRESS;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CHEMOKINE CCL2; CORTICOSTERONE; CYTOKINES; DYSLIPIDEMIAS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPIDS; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOTYPE; PLAQUE, ATHEROSCLEROTIC; STRESS, PHYSIOLOGICAL;

EID: 84892850709     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.11.076     Document Type: Article

References (48)

1. Hossain P., Kawar B., El Nahas M. Obesity and diabetes in the developing world-a growing challenge. NEngl J Med 2007, 356:213-215.
2. Despres J.P., Moorjani S., Lupien P.J., Tremblay A., Nadeau A., Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990, 10:497-511.
3. Rocha V.Z., Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 2009, 6:399-409.
4. Blair S.N., Kampert J.B., Kohl H.W., et al. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. JAm Med Assoc 1996, 276:205-210.
5. Hackam D.G., Anand S.S. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAm Med Assoc 2003, 290:932-940.
6. Rozanski A., Blumenthal J.A., Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999, 99:2192-2217.
7. Zampeli E., Protogerou A., Stamatelopoulos K., et al. Predictors of new atherosclerotic carotid plaque development in patients with rheumatoid arthritis: a longitudinal study. Arthritis Res Ther 2012, 14:R44.
8. Caplan L., Russell A.S., Wolfe F. Steroids for rheumatoid arthritis: the honeymoon revisited (once again). JRheumatol 2005, 32:1863-1865.
9. Giles J.T., Mease P., Boers M., et al. Assessing single joints in arthritis clinical trials. JRheumatol 2007, 34:641-647.
10. Lipson A., Alexopoulos N., Hartlage G.R., et al. Epicardial adipose tissue is increased in patients with systemic lupus erythematosus. Atherosclerosis 2012, 223:389-393.
11. Svec F. Biopotency of corticosterone and dexamethasone in causing glucocorticoid receptor downregulation. JSteroid Biochem 1985, 23:669-671.
12. Spencer R.L., Young E.A., Choo P.H., McEwen B.S. Adrenal steroid type I and type II receptor binding: estimates of invivo receptor number, occupancy, and activation with varying level of steroid. Brain Res 1990, 514:37-48.
13. Monder C., Miroff Y., Marandici A., Hardy M.P. 11 beta-Hydroxysteroid dehydrogenase alleviates glucocorticoid-mediated inhibition of steroidogenesis in rat leydig cells. Endocrinology 1994, 134:1199-1204.
14. Orth D.N. Cushing's syndrome. NEngl J Med 1995, 332:791-803.
15. Pivonello R., Faggiano A., Lombardi G., Colao A. The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol Metab Clin North Am 2005, 34:327-339. [viii].
16. De Leo M., Pivonello R., Auriemma R.S., et al. Cardiovascular disease in Cushing's syndrome: heart versus vasculature. Neuroendocrinology 2012, 92(Suppl.1):50-54.
17. Czeh B., Welt T., Fischer A.K., et al. Chronic psychosocial stress and concomitant repetitive transcranial magnetic stimulation: effects on stress hormone levels and adult hippocampal neurogenesis. Biol Psychiatry 2002, 52:1057-1065.
18. Harvey B.H., Naciti C., Brand L., Stein D.J. Endocrine, cognitive and hippocampal/cortical 5HT 1A/2A receptor changes evoked by a time-dependent sensitisation (TDS) stress model in rats. Brain Res 2003, 983:97-107.
19. Rittenhouse P.A., Lopez-Rubalcava C., Stanwood G.D., Lucki I. Amplified behavioral and endocrine responses to forced swim stress in the Wistar-Kyoto rat. Psychoneuroendocrinology 2002, 27:303-318.
20. Murray F., Smith D.W., Hutson P.H. Chronic low dose corticosterone exposure decreased hippocampal cell proliferation, volume and induced anxiety and depression like behaviours in mice. Eur J Pharmacol 2008, 583:115-127.
21. Pavlides C., Watanabe Y., McEwen B.S. Effects of glucocorticoids on hippocampal long-term potentiation. Hippocampus 1993, 3:183-192.
22. Inoue T., Koyama T. Effects of acute and chronic administration of high-dose corticosterone and dexamethasone on regional brain dopamine and serotonin metabolism in rats. Prog Neuropsychopharmacol Biol Psychiatry 1996, 20:147-156.
23. Nakashima Y., Plump A.S., Raines E.W., Breslow J.L., Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994, 14:133-140.
24. Zhang S.H., Reddick R.L., Piedrahita J.A., Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992, 258:468-471.
25. Matsushima Y., Hayashi S., Tachibana M. Spontaneously hyperlipidemic (SHL) mice: Japanese wild mice with apolipoprotein E deficiency. Mamm Genome 1999, 10:352-357.
26. Matsushima Y., Sakurai T., Ohoka A., et al. Four strains of spontaneously hyperlipidemic (SHL) mice: phenotypic distinctions determined by genetic backgrounds. JAtheroscler Thromb 2001, 8:71-79.
27. Boring L., Gosling J., Cleary M., Charo I.F. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998, 394:894-897.
28. Okabe T., Toda T., Nukitrangsan N., et al. Comparative study of the effect of basal diet formulation, dietary fat and cholesterol levels on the development of aortic atherosclerotic lesions in B6.KOR-Apoeshl mice. JOleo Sci 2010, 59:161-167.
29. Smart J.L., Tolle V., Low M.J. Glucocorticoids exacerbate obesity and insulin resistance in neuron-specific proopiomelanocortin-deficient mice. JClin Invest 2006, 116:495-505.
30. Ni W., Egashira K., Kitamoto S., et al. New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation 2001, 103:2096-2101.
31. Usui S., Hara Y., Hosaki S., Okazaki M. Anew on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. JLipid Res 2002, 43:805-814.
32. Czerwinski S.M., Zak R., Kurowski T.T., Falduto M.T., Hickson R.C. Myosin heavy chain turnover and glucocorticoid deterrence by exercise in muscle. JAppl Physiol 1989, 67:2311-2315.
33. Kumari M., Grahame-Clarke C., Shanks N., Marmot M., Lightman S., Vallance P. Chronic stress accelerates atherosclerosis in the apolipoprotein E deficient mouse. Stress 2003, 6:297-299.
34. Erkut Z.A., Pool C., Swaab D.F. Glucocorticoids suppress corticotropin-releasing hormone and vasopressin expression in human hypothalamic neurons. JClin Endocrinol Metab 1998, 83:2066-2073.
35. Kullo I.J., Hensrud D.D., Allison T.G. Relation of low cardiorespiratory fitness to the metabolic syndrome in middle-aged men. Am J Cardiol 2002, 90:795-797.
36. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
37. Lumeng C.N., Saltiel A.R. Inflammatory links between obesity and metabolic disease. JClin Invest 2011, 121:2111-2117.
38. Schipper H.S., Nuboer R., Prop S., et al. Systemic inflammation in childhood obesity: circulating inflammatory mediators and activated CD14(++) monocytes. Diabetologia 2012, 55:2800-2810.
39. Kleemann R., Zadelaar S., Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008, 79:360-376.
40. Donath M.Y., Shoelson S.E. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011, 11:98-107.
41. Gordon T., Kannel W.B. Multiple risk functions for predicting coronary heart disease: the concept, accuracy, and application. Am Heart J 1982, 103:1031-1039.
42. Ross R. Atherosclerosis-an inflammatory disease. NEngl J Med 1999, 340:115-126.
43. Cavenee W.K., Melnykovych G. Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase in HeLa cells by glucocorticoids. JBiol Chem 1977, 252:3272-3276.
44. Hahn P., Mahler L. The control of cholesterol metabolism and plasma lipid levels in infant rats. Physiol Res 1992, 41:407-410.
45. Oda H., Suzuki Y., Shibata T., Yoshida A. Glucocorticoid-dependent induction of HMG-CoA reductase and malic enzyme gene expression by polychlorinated biphenyls in rat hepatocytes. JNutr Biochem 1999, 10:644-653.
46. Siperstein M.D., Fagan V.M. Feedback control of mevalonate synthesis by dietary cholesterol. JBiol Chem 1966, 241:602-609.
47. Morikawa S., Umetani M., Nakagawa S., et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. JAtheroscler Thromb 2000, 7:138-144.
48. Parker R.A., Pearce B.C., Clark R.W., Gordon D.A., Wright J.J. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. JBiol Chem 1993, 268:11230-11238.